Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015 (2015), Article ID 137136, 8 pages
http://dx.doi.org/10.1155/2015/137136
Research Article

Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of Angiogenesis

1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
2Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
3Center of Cancer Systems Biology, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
4Departments of Oncology and Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Received 19 August 2014; Revised 16 December 2014; Accepted 12 January 2015

Academic Editor: Juliana L. Dreyfuss

Copyright © 2015 Junko Yoshida et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Gupta and C. Illingworth, “Treatments for corneal neovascularization: a review,” Cornea, vol. 30, no. 8, pp. 927–938, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Lee, C. C. Wang, and A. P. Adamis, “Ocular neovascularization: an epidemiologic review,” Survey of Ophthalmology, vol. 43, no. 3, pp. 245–269, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Bachmann, R. S. Taylor, and C. Cursiefen, “Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis,” Ophthalmology, vol. 117, no. 7, pp. 1300.e7–1305.e7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-H. Chang, E. E. Gabison, T. Kato, and D. T. Azar, “Corneal neovascularization,” Current Opinion in Ophthalmology, vol. 12, no. 4, pp. 242–249, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Abdollahi, L. Hlatky, and P. E. Huber, “Endostatin: the logic of antiangiogenic therapy,” Drug Resistance Updates, vol. 8, no. 1-2, pp. 59–74, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Ma, Y. Yao, D. Yuan et al., “Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice,” PLoS ONE, vol. 7, no. 12, Article ID e53449, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Zhuo, Y. Chen, X. Song, and Y. Luo, “Endostatin specifically targets both tumor blood vessels and lymphatic vessels,” Frontiers of Medicine in China, vol. 5, no. 4, pp. 336–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Cursiefen, L. Chen, M. R. Dana, and J. W. Streilein, “Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology,” Cornea, vol. 22, no. 3, pp. 273–281, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. R. J. Campbell, C. M. Bell, J. M. Paterson et al., “Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis,” Ophthalmology, vol. 119, no. 8, pp. 1604–1608, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. F. Martin, M. G. Maguire, S. L. Fine et al., “Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results,” Ophthalmology, vol. 119, no. 7, pp. 1388–1398, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Ueta, H. Mori, A. Kunimatsu, T. Yamaguchi, Y. Tamaki, and Y. Yanagi, “Stroke and anti-VEGF therapy,” Ophthalmology, vol. 118, no. 10, pp. 2093–2093.e2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. D. S. Boyer, J. S. Heier, D. M. Brown, S. F. Francom, T. Ianchulev, and R. G. Rubio, “A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration,” Ophthalmology, vol. 116, no. 9, pp. 1731–1739, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. O'Reilly, T. Boehm, Y. Shing et al., “Endostatin: an endogenous inhibitor of angiogenesis and tumor growth,” Cell, vol. 88, no. 2, pp. 277–285, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Abdollahi, P. Hahnfeldt, C. Maercker et al., “Endostatin's antiangiogenic signaling network,” Molecular Cell, vol. 13, no. 5, pp. 649–663, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Folkman, “Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action,” Experimental Cell Research, vol. 312, no. 5, pp. 594–607, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Boehm-Viswanathan, “Is angiogenesis inhibition the Holy Grail of cancer therapy?” Current Opinion in Oncology, vol. 12, no. 1, pp. 89–94, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. C. Yang, L. Haworth, R. M. Sherry et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” The New England Journal of Medicine, vol. 349, no. 5, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. S. B. Sunshine, S. M. Dallabrida, E. Durand et al., “Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 28, pp. 11306–11311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Yu, K. S. Moulton, M. K. Khan et al., “E-selectin is required for the antiangiogenic activity of endostatin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 21, pp. 8005–8010, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Pradilla, F. G. Legnani, G. Petrangolini et al., “Local delivery of a synthetic endostatin fragment for the treatment of experimental gliomas,” Neurosurgery, vol. 57, no. 5, pp. 1032–1040, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. T.-Y. Lee, R. M. T. T. Sjin, S. Movahedi et al., “Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy,” Clinical Cancer Research, vol. 14, no. 5, pp. 1487–1493, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. S. Gordon, K. Margolin, M. Talpaz et al., “Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 843–850, 2001. View at Google Scholar · View at Scopus
  24. R. Grossman, B. Tyler, L. Hwang et al., “Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin: laboratory investigation,” Journal of Neurosurgery, vol. 115, no. 6, pp. 1139–1146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. V. Sefton, L. R. Brown, and R. S. Langer, “Ethylene-vinyl acetate copolymer microspheres for controlled release of macromolecules,” Journal of Pharmaceutical Sciences, vol. 73, no. 12, pp. 1859–1861, 1984. View at Publisher · View at Google Scholar · View at Scopus
  26. R. J. Tamargo, R. A. Bok, and H. Brem, “Angiogenesis inhibition by minocycline,” Cancer Research, vol. 51, no. 2, pp. 672–675, 1991. View at Google Scholar · View at Scopus
  27. I. Celik, O. Sürücü, C. Dietz et al., “Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve,” Cancer Research, vol. 65, no. 23, pp. 11044–11050, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. W. Slaton, P. Perrotte, K. Inoue, C. P. N. Dinney, and I. J. Fidler, “Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule,” Clinical Cancer Research, vol. 5, no. 10, pp. 2726–2734, 1999. View at Google Scholar · View at Scopus
  29. D. Panigrahy, S. Singer, L. Q. Shen et al., “PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Javaherian, T.-Y. Lee, R. M. T. T. Sjin, G. E. Parris, and L. Hlatky, “Two endogenous antiangiogenic inhibitors, endostatin and angiostatin, demonstrate biphasic curves in their antitumor profiles,” Dose-Response, vol. 9, no. 3, pp. 369–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. W.-L. Chen, C.-T. Lin, N.-T. Lin et al., “Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis,” Investigative Ophthalmology & Visual Science, vol. 50, no. 4, pp. 1659–1665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. L. D. Ormerod, A. Garsd, C. V. Reddy, S. A. Gomes, M. B. Abelson, and K. R. Kenyon, “Dynamics of corneal epithelial healing after an alkali burn. A statistical analysis,” Investigative Ophthalmology and Visual Science, vol. 30, no. 8, pp. 1784–1793, 1989. View at Google Scholar · View at Scopus